Common questions and answers in the management of hypertension: alcohol's (other) dark side [0.03%]
高血压管理中的常见问题解答之酒精的“另一面”
Christopher B McFadden,Raymond R Townsend
Christopher B McFadden
Joel Handler
Joel Handler
Arun Malhotra,Debbie Cohen,Charles Syms et al.
Arun Malhotra et al.
Normotensive and hypertensive patients develop peripheral arterial disease. The authors hypothesized that significant changes in lower extremity blood pressures occur upon standing, which could play a role in the pathogenesis of peripheral ...
Endothelins and markers of renal damage in recently diagnosed hypertensive patients [0.03%]
近期新诊断的高血压患者中的内皮素与肾损害标志物之间的关系
Antonia Maldonado-Martín,Dolores Rueda-Illescas,Blas Gil-Extremera et al.
Antonia Maldonado-Martín et al.
Endothelin has been identified as a potent vasoconstrictor. The aim of this study was to evaluate urinary endothelins and their relation to other markers of renal damage, such as microalbuminuria, creatinine, and N-acetyl-beta-glucosaminida...
Why do treated hypertensives suffer strokes? An internist's perspective [0.03%]
为什么接受治疗的高血压患者会发生中风？内科医生的观点
Geza Simon
Geza Simon
Despite widespread treatment of hypertension, stroke continues to be the third leading cause of death in the United States. Antihypertensive therapy is more effective in preventing hemorrhagic strokes than ischemic strokes. In order to unde...
Ray W Gifford Jr
Ray W Gifford Jr
How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? [0.03%]
原发性高血压患者轻度肾功能损害的患病率和相关因素分析
Julían Segura,Carlos Campo,Luis M Ruilope
Julían Segura
Recent analyses of the influence of renal function on the cardiovascular outcome in essential hypertensive patients have confirmed the relevance of the kidney in cardiovascular prognosis even in the initial stages of renal failure. The eval...
Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements [0.03%]
奥美沙坦酯——一种新的血管紧张素Ⅱ受体拮抗剂的降压疗效评价：动态血压监测结果
Joel M Neutel,William J Elliott,Joseph L Izzo et al.
Joel M Neutel et al.
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypert...
Marvin Moser
Marvin Moser
L Michael Prisant,Wayne Herman
L Michael Prisant
Gingival overgrowth occurs with phenytoin, cyclosporin, and calcium antagonists. It can be disfiguring and painful. The prevalence of gingival overgrowth with the use of calcium antagonists may be as high as 38%. The prevalence with nifedip...